Ery­tech shares soar on pos­i­tive re­sults for PhI­Ib pan­cre­at­ic can­cer tri­al; Ar­Qule’s tivan­ti­nib fails yet again in PhI­II can­cer study

→ France’s Ery­tech Phar­ma says it gar­nered pos­i­tive da­ta in a Phase IIb study of eryas­pase com­bined with chemo for sec­ond-line metasta­t­ic pan­cre­at­ic can­cer, send­ing shares $ERYP rock­et­ing up 75%. The drug hits its co-pri­ma­ry end­points with sig­nif­i­cant im­prove­ments for pro­gres­sion-free sur­vival as well as over­all sur­vival. Pas­cal Ham­mel, prin­ci­pal in­ves­ti­ga­tor of the study, com­ment­ed: “These re­sults gen­er­at­ed by eryas­pase in com­bi­na­tion with the stan­dard of care are high­ly en­cour­ag­ing and com­pare fa­vor­ably to gem­c­itabine or FOL­FOX treat­ment ad­min­is­tered alone. The re­sults of this study sup­port eryas­pase as a po­ten­tial treat­ment op­tion for pa­tients with metasta­t­ic pan­cre­at­ic can­cer in the sec­ond-line set­ting.”

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN